Brief: Aura Biosciences To Present Updated Phase 2 Data Evaluating Bel-Sar For Early-Stage Choroidal Melanoma At AAO 2023

Aura Biosciences

31/10/2023 20:23

Oct 31 (Reuters) - Aura Biosciences Inc  AURA.O :
    * AURA BIOSCIENCES TO PRESENT UPDATED PHASE 2 DATA
EVALUATING
SUPRACHOROIDAL ADMINISTRATION OF BELZUPACAP SAROTALOCAN
(BEL-SAR) FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH
EARLY-STAGE CHOROIDAL MELANOMA AT AAO 2023

Source text for Eikon:  ID:nBwmF9fHa 
Further company coverage:  AURA.O 

 ((Reuters.Briefs@thomsonreuters.com;))